A methodological framework for drug development in rare diseases.

Area of Science:

• Pharmacometrics
• Translational Research
• Drug Development

Background:

• Orphan drug development faces challenges due to disease severity and small patient populations, hindering traditional randomized controlled trials (RCTs).
• There is a critical need for high-quality, ethically sound medicines developed without unnecessary patient trials.
• Efficient methodologies are required to accelerate the development of effective orphan drugs.

Purpose of the Study:

• To establish a generalizable framework for selecting optimal drug/endpoint/design combinations in orphan drug development.
• To identify the most relevant drugs for phase III RCTs in specific patient populations for each disease.
• To determine the most effective trial design for each selected drug candidate.

Main Methods:

• Utilizing in silico phase III RCT simulations to identify optimal trial designs.
• Conducting statistical analysis of existing clinical databases.
• Employing integrative modeling, combining disease mathematical models with pharmacokinetic-pharmacodynamic (PK/PD) models for drug candidates.

Main Results:

• The study provides a strategic approach for selecting drugs and trial designs in orphan drug development.
• In silico simulations facilitate the optimization of clinical trial parameters.
• The framework supports the identification of best-performing drug/endpoint/design combinations.

Conclusions:

• Accelerating orphan drug development requires novel methods in translational research and personalized medicine.
• This in silico approach offers significant potential for improving clinical trial design.
• The findings can contribute to European Medicines Agency (EMA) guidelines for orphan drug development.